References
- Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413–420. doi: 10.1111/j.1538-7836.2008.03270.x
- Collins PW, Fischer K, Morfini M, et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17(1):2–10. doi: 10.1111/j.1365-2516.2010.02370.x
- Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1–158. doi: 10.1111/hae.14046
- Ragni MV, Croteau SE, Morfini M, et al. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(7):1437–1441. doi: 10.1111/jth.14153
- McEneny-King A, Chelle P, Foster G, et al. Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization. J Pharmacokinet Pharmacodyn. 2019;46(1):411–426. doi: 10.1007/s10928-019-09634-7
- Lippi G, Salvagno G, Montagnana M, et al. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost. 2012;38(6):565–575. doi: 10.1055/s-0032-1315961
- Aarsand AK, Kristoffersen AH, Sandberg S, et al. The European biological variation study (EuBIVAS): biological variation data for coagulation markers estimated by a Bayesian model. Clin Chem. 2021;12:1–12.
- Huang K, Zhen Y, Li G, et al. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A. Haemophilia. 2021;27(4):e450–e457.
- Blanchette VS, Zunino L, Grassmann V, et al. A practical, one-clinic visit protocol for pharmacokinetic profile generation with the ADVATE myPKFiT dosing tool in severe hemophilia A subjects. Thromb Haemost. 2021;121(10):1326–1336. doi: 10.1055/a-1376-0970
- McEneny-King A, Yeung CHT, Edginton AN, et al. Clinical application of web accessible population pharmacokinetic service—hemophilia (WAPPS-Hemo): patterns of blood sampling and patient characteristics among clinician users. Haemophilia. 2020;26(1):56–63. doi: 10.1111/hae.13882
- Milos M, Coen Herak D, Mahmoud Hourani Soutari N, et al. Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype. Int J Lab Hematol. 2021;43(2):273–280. doi: 10.1111/ijlh.13347
- Salvagno GL, Demonte D, Poli G, et al. Impact of low volume citrate tubes on results of first-line hemostasis testing. Int J Lab Hematol. 2019;41(4):472–477. doi: 10.1111/ijlh.13028
- Keating GM. BAY 81-8973 (Octocog Alfa; Kovaltry®): a review in haemophilia A. BioDrugs. 2016;30(5):453–459. doi: 10.1007/s40259-016-0191-4
- Siegel JE, Bernard DW, Swami VK, et al. Monitoring heparin therapy: APTT results from partial- vs full-draw tubes. Am J Clin Pathol. 1998;110(2):184–187. doi: 10.1093/ajcp/110.2.184
- McEneny-King A, Foster G, Iorio A, et al. Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the web-accessible population pharmacokinetic service – hemophilia (WAPPS-Hemo). JMIR Res Protoc. 2016;5(4):e232. doi: 10.2196/resprot.6559